Postmarketing Requirement (PMR) Non-Interventional 2-armed Study to Evaluate the Safety of octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, with a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events (TEEs) (GAM5-28)

20/08/2015
20/08/2015
EU PAS number:
EUPAS10738
Study
Ongoing
Documents
Study protocol
Initial protocol
English (871.1 KB - PDF) View document
Study results
Study report
Other information